ISRCTN14123846进行中（未招募）3 期
An open-label, multicenter extension study to evaluate the long-term safety and tolerability of faricimab administered in patients previously enrolled in studies sponsored by F. Hoffmann-La Roche Ltd
F. Hoffman-la Roche0 个研究点目标入组 350 人开始时间: 2021年8月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Previous enrollment in and completion of any faricimab parent study without study or study drug discontinuation.
- •2. Enrolled in the mainland of China
- •3. Signed Informed Consent Form
- •4. Ability and willingness to comply with the study protocol, in the investigator's judgment
排除标准
- •1. Pregnant or breastfeeding, or intending to become pregnant during the study or within 28 days after the final ITV injection of faricimab
- •2. Women of childbearing potential must have a negative urine pregnancy test result within 28 days prior to initiation of study treatment. If the urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.
研究者
相似试验
进行中（未招募）
不适用
An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.EUCTR2004-000047-18-SEBiogen Idec Ltd.1,900
进行中（未招募）
不适用
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.Type 2 diabetes MellitusMedDRA version: 7Level: lowClassification code 10012613EUCTR2005-004268-21-HUF. Hoffmann-La Roche Ltd370
进行中（未招募）
不适用
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.EUCTR2005-004268-21-DEF. Hoffmann-La Roche Ltd370
进行中（未招募）
不适用
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.Type 2 diabetes MellitusMedDRA version: 7Level: lowClassification code 10012613EUCTR2005-004268-21-GBF. Hoffmann-La Roche Ltd370
进行中（未招募）
1 期
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Alagille Syndrome (ALGS) or Progressive Familial Intrahepatic Cholestasis (PFIC)Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)MedDRA version: 17.1 Level: SOC Classification code 10010331 Term: Congenital, familial and genetic disorders System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 17.1 Level: PT Classification code 10053870 Term: Alagille syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-000906-20-GBShire Human Genetic Therapies Inc999,999